如果你秃顶了，想让自己的头发长出来，那么下面的报道对你绝对有帮助。近日，一项刊登于国际杂志FASEB Journal上的研究报告指出，一种FDA批准的青光眼药物比马前列素，可以促使人们头发再生长，而且该药物已经在增长个体眼睫毛上进行了商业的应用，研究者表示，实际上这种药物还可以促使个体的头发再生。
青光眼药物比马前列素可促进头发再生
比马前列素是合成的前列酰胺F2α衍生物,能选择性地模拟体内产生的前列胺的作用，使房水产生速度增加，房水外流阻力减小，通过增加小梁网通道和葡萄膜巩膜通道的房水流出量而降低眼压(IOP)，被认为是目前降眼压作用最强的局部抗青光眼药物。
研究者Valerie Randall表示，我们希望这项研究有助于开发出治疗许多人头发少或者谢顶的疗法，未来研究中应该增加关于头发毛囊如何工作以及这种新型疗法如何治疗头发生长障碍的问题。
本项研究中，研究者进行了三组实验，两组实验涉及人类细胞和其它的小鼠细胞，对人类细胞的实验包括使用让毛囊在器官培养液中生长，就好比让头发毛囊在头皮中生长一样。这些实验结果显示，药物比马前列素可以促使头发再生。第三项实验包括应用比马前列素到小鼠皮肤的秃斑上，正如在人类细胞中一样，比马前列素也可以促使小鼠秃斑上的头发再生。
这项研究发现将会随着伟哥给中年男性带来的福利一样，让他们摆脱秃顶。目前药物比马前列素已经得到批准可以应用于人类个体中，而且其安全性已经得到了评估。而且这也是研究者在科研中的一个新发现，将治疗青光眼的药物用于治疗头发缺失。
The prostamide-related glaucoma therapy, bimatoprost, offers a novel approach for treating scalp alopecias
Karzan G. Khidhir, David F. Woodward, Nilofer P. Farjo, Bessam K. Farjo, Elaine S. Tang, Jenny W. Wang, Steven M. Picksley and Valerie A. Randall
Balding causes widespread psychological distress but is poorly controlled. The commonest treatment, minoxidil, was originally an antihypertensive drug that promoted unwanted hair. We hypothesized that another serendipitous discovery, increased eyelash growth side-effects of prostamide F2α-related eyedrops for glaucoma, may be relevant for scalp alopecias. Eyelash hairs and follicles are highly specialized and remain unaffected by androgens that inhibit scalp follicles and stimulate many others. Therefore, we investigated whether non-eyelash follicles could respond to bimatoprost, a prostamide F2α analog recently licensed for eyelash hypotrichosis. Bimatoprost, at pharmacologically selective concentrations, increased hair synthesis in scalp follicle organ culture and advanced mouse pelage hair regrowth in vivo compared to vehicle alone. A prostamide receptor antagonist blocked isolated follicle growth, confirming a direct, receptor-mediated mechanism within follicles; RT-PCR analysis identified 3 relevant receptor genes in scalp follicles in vivo. Receptors were located in the key follicle regulator, the dermal papilla, by analyzing individual follicular structures and immunohistochemistry. Thus, bimatoprost stimulates human scalp follicles in culture and rodent pelage follicles in vivo, mirroring eyelash behavior, and scalp follicles contain bimatoprost-sensitive prostamide receptors in vivo. This highlights a new follicular signaling system and confirms that bimatoprost offers a novel, low-risk therapeutic approach for scalp alopecias.The prostamide-related glaucoma therapy, bimatoprost, offers a novel approach for treating scalp alopecias.
